Preeclampsia Drugs Market Report 2024 | Share, Trends, Growth Demand, overview By 2033

"The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.

Preeclampsia Drugs Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.

The Market Size Is Expected To Reach $1.89 billion In 2028 At A CAGR Of 10.9% :

The preeclampsia drugs market size has grown rapidly in recent years. It will grow from $1.13 billion in 2023 to $1.25 billion in 2024 at a compound annual growth rate (CAGR) of 10.7%. The growth in the historic period can be attributed to increased maternal health awareness, research and development, neonatal health concerns, early detection.

The preeclampsia drugs market size is expected to see rapid growth in the next few years. It will grow to $1.89 billion in 2028 at a compound annual growth rate (CAGR) of 10.9%. The growth in the forecast period can be attributed to personalized medicine, non-invasive diagnostic tools, targeted therapies, health equity initiatives. Major trends in the forecast period include preventive strategies, patient-centered care, continuous monitoring, regulatory focus.

Request A Sample Of This Report - https://www.thebusinessresearchcompany.com/sample.aspx?id=13025&type=smp

Preeclampsia Drugs Market Major Segments
The preeclampsia drugs market covered in this report is segmented -

1) By Type: Mild Preeclampsia; Severe Preeclampsia
2) By Treatment: Medication to Lower Hypertension (B.P); Corticosteroids; Anticonvulsants Medication
3) By Route of Administration: Oral; Parenteral; Other Route of Administration
4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacies; Other Distribution Channels
5) By End-User: Hospitals; Specialty Clinics; Diagnostic Centers; Other End-Users

Key Driver - Rising Diabetes Cases In Pregnancy Fueling Growth In The Preeclampsia Drug Market

The rise in diabetes cases among pregnant women is expected to propel the growth of the preeclampsia drug market going forward. Diabetes is a metabolic disease that is chronic and characterized by high blood glucose (or blood sugar) levels. Preeclampsia is a harmful pregnancy condition with elevated blood pressure and organ damage. Metformin, a preeclampsia medicine, is widely used in pregnant women with preterm preeclampsia. For instance, in December 2022, according to the National Library of Medicine, a US-based biomedical library and center of biomedical informatics, the total incidence of gestational diabetes mellitus (GDM) was 20,865 cases, an increase of 6.56% in 2022. Therefore, the rise in diabetes cases among pregnant women will drive the preeclampsia drug market.

Customise This Report As Per Your Requirements - https://www.thebusinessresearchcompany.com/Customise?id=13025&type=smp

Prominent Trend - Leading Companies In The Preeclampsia Medicine Market Pursuing Innovative Drug Solutions

Major companies in the preeclampsia medicine market are focusing on developing cutting-edge drug solutions to boost their market position. For instance, in March 2023, Comanche Biopharma Corp., a US-based biopharmaceutical firm, revealed that the Food and Drug Administration (FDA) has approved an investigational new drug (IND) application for CBP-4888 Comanche's unique siRNA treatment to treat preeclampsia. CBP-4888 is a siRNA therapy given subcutaneously and reduces the synthesis of soluble fms-like tyrosine kinase-1 (sFLT1) in the placenta. The placenta's overproduction of the protein sFLT1, which enters the mother's circulation, is the primary cause of preeclampsia. CBP-4888 can alleviate the symptoms of preeclampsia, such as high blood pressure and organ damage and may allow for the safe extension of pregnancy.

Preeclampsia Drugs Market Players
Major players in the preeclampsia drugs market are AbbVie Inc., Pfizer Inc., Johnson & Johnson Co, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A., Celgene Corp, Thermo Fisher Scientific Inc., AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Takeda Pharmaceuticals Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Siemens Healthcare GmbH, Boehringer Ingelheim Group, Viatris Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Union Chimique Belge SA, Otsuka Pharmaceutical Co. Ltd., Kyowa Kirin Co Ltd., Mallinckrodt Pharmaceuticals Limited, Comanche Biopharma Corp, Genentech Inc., Diabetomics Inc.

View The Full Report Here - https://www.thebusinessresearchcompany.com/report/preeclampsia-drugs-global-market-report

Largest And Fastest Growing Region In The Market
North America was the largest region in the preeclampsia drugs market in 2023. The regions covered in preeclampsia drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Preeclampsia Drugs Market Report Structure
3. Preeclampsia Drugs Market Trends And Strategies
4. Preeclampsia Drugs Market - Macro Economic Scenario
5. Preeclampsia Drugs Market Size And Growth
…..
27. Preeclampsia Drugs Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.